| First Author | Ashcroft AJ | Year | 2003 |
| Journal | Immunity | Volume | 19 |
| Issue | 6 | Pages | 849-61 |
| PubMed ID | 14670302 | Mgi Jnum | J:86997 |
| Mgi Id | MGI:2682544 | Doi | 10.1016/s1074-7613(03)00326-1 |
| Citation | Ashcroft AJ, et al. (2003) Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity 19(6):849-61 |
| abstractText | Autoimmune associated bone disease and intestinal inflammation are closely linked with deregulation and hyperactivation of autoreactive CD4 T cells. How these T cells are activated and mediate disease is not clear. Here we show that in the Interleukin 2-deficient mouse model of autoimmunity spontaneous osteopenia and colitis are caused by increased production of the ligand for receptor activator of NFkappaB (RANKL). RANKL acting via its receptor, receptor activator of NFkappaB (RANK), increases bone turnover and promotes intestinal dendritic cell (DC) survival in vivo. Modulation of RANKL-RANK interactions with exogenous recombinant osteoprotegerin (Fc-OPG) reverses skeletal abnormalities and reduces colitis by decreasing colonic DC numbers. This study identifies a common causal link between bone disease and intestinal inflammation and establishes the importance of DC in mediating colonic inflammation in vivo. |
